ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

By deducing the possible ancient forms of a bacterial enzyme, OIST scientists have resurrected one of its ancestral versions, ...

In all living organisms, DNA contains the code that defines cellular structures and functions. An enzyme called RNA ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

LMU researchers have investigated how cationic polymers organize on a molecular level when transporting RNA drugs.

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

This research report explores the global RNA sequencing market, providing an analysis of its trends and projections through 2029. It breaks down the market by product, technology, application, end ...

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.

Researchers have developed TRISCO, a cutting-edge microscopy method that enables 3D RNA analysis in whole, intact mouse ...